



SARS-CoV-2 Infection in Women and Children

Guest Editor:

Dr. Narayanaiah Cheedarla

Department of Pathology and
Laboratory Medicine, Emory
University School of Medicine,
Atlanta, GA, USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

The SARS-CoV-2 vaccine has been recommended for pregnant women, but survey studies show wildly different results around the world in terms of the willingness to be vaccinated during pregnancy. The cumulative uptake of the SARS-CoV-2 vaccine among pregnant women appears to remain low. A lack of information on the impact of vaccination during pregnancy on fetal safety is one of the most important factors preventing pregnant women from being immunized, thereby preventing herd immunity from being achieved.

Vaccinating as many people as possible is crucial if we are to rebuild a normal way of life. Vaccination campaigns are urgently needed to increase confidence in vaccines to help reduce the spread of infection and possible consequences during pregnancy.

This Special Issue focuses on the immune response of vaccinated pregnant women, the safety and efficacy of COVID-19 vaccination during pregnancy, and the vaccine's impact on maternal and fetal immune responses. We welcome all types of submissions, including original research, reviews, case reports, etc., for this Special Issue. We look forward to receiving your contributions!





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com